Bart Frazzitta was told he had a 5% chance of surviving esophageal cancer. Twenty-five years later, he's still here and ...

Two final-year Medicine students design consultation tools thanks to a grant from the Cris Foundation against Cancer. After a ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

New statistics show Britain has the highest cases of esophageal cancer in the entire Europe, mostly for those under 40 years ...

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...

A new artificial intelligence model developed by Stanford Medicine combines clinical notes and pathology images to predict ...

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...

“Locally advanced unresectable or metastatic gastroesophageal adenocarcinoma remains a challenging disease to treat and a leading cause of cancer death worldwide,” Dr. Gregory Lubiniecki, Vice ...

Patients who traveled to high-volume centers for esophagectomy experienced better outcomes than those who sought treatment ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

The following is a summary of “Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer,” published ...

Netherlands: A recent retrospective cohort study has shed light on the connection between esophageal Candida infection and an ...